Panacea Biotec : Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases

Press Release:

nacea Biotec

lnnov,:..it'c», ,-,.... SC/tpport of {t'fe

For Immediate Release

New Delhi: 29th March, 2017: Panacea Biotec, one of India's leading research based Biopharmaceutical Company, is pleased to announce launch of World's First Fully Liquid whole cell Pertussis (wP) based Hexavalent Combination Vaccine, EasySix™, a vaccine Researched, Developed and Manufactured by Panacea Biotec in India. EasySix is indicated for primary immunization to protect newborn babies against six common preventable diseases, viz . Diphtheria, Tetanus, Whooping Cough, Meningitis (due to H. Influenza type b}, Hepatitis B and Polio.

EasySix™ is a fully liquid ready-to-use hexavalent vaccine made using high quality antigens complying to WHO's cGMP requirements. EasySix is found to be immunogenic, safe and well tolerated in Phase I and Phase Ill clinical trial conducted in various hospitals across India. EasySix showed comparable immunogenicity and fewer number of subjects reported less side effects when compared with comparator of Pentavalent Vaccine and IPV vaccine given separately. The fully liquid 6-in-1 combination vaccine EasySix™ requires no reconstitution, therefore saves time, is convenient and minimizes chances of error.

Panacea Biotec has been developing superior innovative vaccines against infective diseases for more than three decades and has made immense contribution in disease prevention and reducing child mortality, through innovative vaccine development, production and marketing.

Panacea Biotec is well acknowledged by the UN Health Agencies in partnering for the Polio eradication program and has supplied billions of doses of WHO Pre-Qualified Polio vaccine across the globe. Panacea Biotec is the first company to have developed World's first fully­ liquid Quadravalent Vaccine Easyfour-TT (DTwP-Hib) Pentavalent Vaccine Easyfive-TT (DTwP­ HepB-Hib), monovalent Polio vaccine against Type 1 and Type 3 Polio virus, Bivalent Polio Vaccine against Type 1& 3 Polio virus.

Commenting on the development Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd. said "After 10 years of consistent R&D effort, Panacea Biotec takes imense pleasure and

Panacea Biotec Ltd.

CIN:L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.:+91-1762-50

{!nacea Biotee

lnnovt:...it'on ,;, SCApport of (t'fe

is proud to introduce the World's First Fully Liquid wP based hexavalent vaccine, EasySix. Panacea Biotec is committed to protecting babies from Vaccine-Preventable diseases and will remain committed to its mission 'Innovation in Support of Life'."

About Panacea Biotec

Panacea Biotec is one of India's leading research based Biopharmaceutical Company with established research, manufacturing and marketing capabilities . Panacea Biotec is one of the largest vaccine producers in India and is one of the leading Biotechnology Companies. The Company has also been ranked amongst the top 60 pharmaceutical companies (AIOCD AWACS-MAT MAR-2016) in India. The product portfolio of Panacea Biotec includes highly innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems. Panacea Biotec has introduced its products in over 20 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations. The company's state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, European and WHO cGMP standards. The company has around 2,500 employees including around 120 scientists working across 4 R&D centers of the Company .

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

For more information, please contact -

Mr P. D. Karan

Vice President - Corporate Communication & Business Development 8-1 Extn. I A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi - 110044, INDIA

Tel: + 911141679000 Extn. 1406,41578080 (Direct)

Fax + 911141578002

Mobile: + 91 9312693040

Email: pdkaran@panaceabiotec.com Web: www.panaceabiotec.com

Panacea Biotec Ltd.

CIN:L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.:+91-1762-505900, Fax: +91-1762-505906.